Orismilast的药理学:一种强效选择性PDE4抑制剂
本研究在体外、离体和体内评估了第二代PDE4抑制剂orismilast的酶活性与抗炎作用。Orismilast选择性抑制PDE4及其B、D亚型剪接变体,抑制全血和PBMC中TNFα及Th1、Th17、Th2相关细胞因子分泌。在小鼠慢性噁唑酮诱导耳部皮肤炎症模型中,10和30 mg/kg剂量均显著降低耳厚度和炎症标志物(p < 0.0001)。
要点
- Orismilast在体外选择性抑制PDE4,强效抑制PDE4B和PDE4D亚型剪接变体。
- Orismilast抑制全血和PBMC产生TNFα及Th1、Th17、Th2相关细胞因子。
- 小鼠体内10和30 mg/kg orismilast显著降低耳厚度和炎症标志物(p < 0.0001)。
核心结论
- Orismilast在多种临床前模型中显示选择性强效的PDE4抑制和广谱抗炎活性,结果支持口服orismilast作为银屑病、特应性皮炎和化脓性汗腺炎等慢性炎症性皮肤病新治疗选择的临床开发。
研究设计与样本
- 体外使用308 nM单浓度orismilast检测PDE1-11酶活性,并在放射测定中进一步评估PDE4选择性和抑制效力。
- 离体在人全血和人外周血单个核细胞(PBMC)中检测orismilast对细胞因子分泌和抑制谱的影响。
- 体内在小鼠慢性噁唑酮诱导耳部皮肤炎症模型中口服给予orismilast,分析耳厚度和炎症细胞因子。
主要发现
- Orismilast在体外选择性抑制PDE4,并强效抑制PDE4B和PDE4D亚型剪接变体。
- Orismilast抑制全血和PBMC产生肿瘤坏死因子α(TNFα),并抑制PBMC分泌Th1(TNFα和IFNγ)、Th17(IL-22和IL-23)和Th2(IL-4、IL-5和IL-13)相关细胞因子。
- 在小鼠体内,10和30 mg/kg剂量orismilast分别显著降低耳厚度和炎症标志物(p < 0.0001)。
关键数值与推荐
- 体外PDE1-11酶活性检测使用308 nM单浓度orismilast。
- 小鼠体内10和30 mg/kg剂量orismilast显著降低耳厚度和炎症标志物(p < 0.0001,分别)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There remains an unmet need for oral medications that are safe and efficacious for long-term management of chronic inflammatory skin diseases (CISD). Inhibition of phosphodiesterase 4 (PDE4) can modulate a broad range of pro-inflammatory cytokines that play a major role in CISD pathogenesis. Orismilast is a second generation PDE4 inhibitor in clinical development for CISD treatment. OBJECTIVES: The objective of this study was to examine the PDE4 enzymatic activity and anti-inflammatory effects of orismilast in vitro, ex vivo, and in vivo. METHODS: The PDE1-11 enzymatic activity of orismilast was tested in vitro using a single concentration of 308 nM orismilast. The PDE4 selectivity and inhibitory potency was further examined in a radiometric assay. Orismilast was tested on human whole blood and human peripheral blood mononuclear cells (PBMC) to determine effects on its cytokine secretion and inhibition profile ex vivo. Orismilast was orally administered in a murine model of chronic oxazolone-induced ear skin inflammation. Ear thickness, a marker of inflammation, and inflammatory cytokines were analysed. RESULTS: Orismilast selectively inhibited PDE4 and demonstrated potent inhibition of PDE4B and PDE4D subtype splice variants in vitro. Orismilast inhibited whole blood and PBMC production of tumour necrosis factor α (TNFα), and the secretion of T-helper (Th)1 (TNFα and IFNγ), Th17 (IL-22 and IL-23), and Th2 (IL-4, IL-5, and IL-13) related cytokines in PBMC. In vivo, 10 and 30 mg/kg doses of orismilast significantly reduced ear thickness and inflammation markers (p < 0.0001, respectively). CONCLUSION: Orismilast displayed selective and potent PDE4 inhibition and broad-spectrum anti-inflammatory activity in several pre-clinical models. The results of the study support clinical development of oral orismilast as a novel treatment option for CISD including psoriasis, atopic dermatitis, and hidradenitis suppurativa.
引用
- Silverberg JI, French LE, Warren RB, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. J Eur Acad Dermatol Venereol. 2023. PMID: 36527389. doi:10.1111/jdv.18818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。